Background: Traditional site-monitoring techniques are not optimal in finding data fabrication and other nonrandom data distributions with the greatest potential for jeopardizing the validity of study results. TransCelerate BioPharma conducted an experiment testing the utility of statistical methods for detecting implanted fabricated data and other signals of noncompliance. Methods: TransCelerate tested statistical monitoring on a data set from a chronic obstructive pulmonary disease (COPD) clinical study with 178 sites and 1554 subjects. Fabricated data were selectively implanted in 7 sites and 43 subjects by expert clinicians in COPD. The data set was partitioned to simulate studies of different sizes. Analyses of vital signs, spirometry, visit dates, and adverse events included distributions of standard deviations, correlations, repeated values, digit preference, and outlier/inlier detection. An interpretation team, including clinicians, statisticians, site monitoring, and data management, reviewed the results and created an algorithm to flag sites for fabricated data. Results: The algorithm identified 11 sites (19%), 19 sites (31%), 28 sites (16%), and 45 sites (25%) as having potentially fabricated data for studies 2A, 2, 1A, and 1, respectively. For study 2A, 3 of 7 sites with fabricated data were detected, 5 of 7 were detected for studies 2 and 1A, and 6 of 7 for study 1. Except for study 2A, the algorithm had good sensitivity and specificity (>70%) for identifying sites with fabricated data. Conclusions: We recommend a crossfunctional, collaborative approach to statistical monitoring that can adapt to study design and data source and use a combination of statistical screening techniques and confirmatory graphics.
Introduction
Traditional site-monitoring techniques may find random data errors, but they are not optimal in identifying data fabrication and other nonrandom data distributions with greatest potential for jeopardizing the validity of study results. 1, 2 One strategy being used is statistical monitoring, or the use of various statistical methods during study conduct to detect data anomalies suggestive of fabrication or noncompliance. 1, [3] [4] [5] The multicentric nature of most clinical trials offers an opportunity to check the plausibility of data from one site against data from all other sites. 3 Statistical monitoring relies on the highly structured nature of data because each protocol is expected to be implemented consistently at all sites. 4 Statistical checks are powerful tools because the multivariate structure and/or time dependence of variables are sensitive to deviations and hard to mimic. Fabricated data, even if plausible from a univariate perspective, are likely to exhibit abnormal multivariate patterns that are detectable statistically. Statistical methods used to detect data anomalies can be applied to all trials; however, many methods are less reliable for small trials or large trials with small numbers of subjects per site. 6 An objective of a previous TransCelerate BioPharma publication on data-quality issues 7 was to provide recommendations based on best practices for detecting data-integrity issues early in study conduct to allow implementation of meaningful corrective and preventive actions. A review of the literature included reports evaluating the utility of statistical methods to detect data anomalies suggestive of data-integrity issues. However, previous work did not sufficiently focus on ongoing pharmaceutical industry-sponsored studies. 5, 6, [8] [9] [10] The current article is a continuation of the previous publication 7 and incorporates findings from that work in our conclusions and recommendations.
Building on prior research, [3] [4] [5] [6] [8] [9] [10] TransCelerate tested statistical-monitoring methods on a biopharmaceutical industry-sponsored clinical study database under conditions partially mimicking those found during real-world study conduct. The objective of this experiment was to detect data anomalies suggestive of noncompliance, but it primarily focused on intentionally fabricated data because of the potential difficulty in detecting this type of noncompliance. This experiment used a combination of contrived and real-world conditions and does not represent a true test in actual clinical study conditions. The objectives of this project were as follows:
1. Examine the ability of statistical monitoring to detect implanted fabricated data and other data anomalies suggestive of noncompliance. 2. Determine which statistical methods are the most useful in high-and low-data volume conditions and describe the effect of data volume on the reliability of the statistical output. 3 . Determine what information can be drawn from statistical output and suggest optimal use of graphical and other data-visualization techniques. 4. Explore the best use of an interpretation team and strategies for interpreting statistical signals with company operational and clinical experts (Data-Science Model).
Methods and Materials
A TransCelerate member company provided a clean, deidentified clinical database from a randomized, double-blind, placebo-controlled, study in chronic obstructive pulmonary disease (COPD) with a locked database.
Selection of Sites and Subjects for Implanting Fabricated Data
Systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse rate were selected because these vital sign evaluations were measured at every visit. Forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) were selected because the data were collected serially as well as produced mechanistically and evaluated centrally, thus significantly reducing the chance for human error. Selected data were deleted and replaced with fabricated plausible data.
Seven sites were randomly chosen from all sites with 12 or more randomized subjects (range, 12-32). The number of subjects was later reduced for studies 1A and 2A as explained below.
Approximately 30% (range, 25%-43%) of subjects at the 7 sites were selected to receive fabricated data. For the selected data fields, all data were deleted except for the screening visit, which was provided for reference. The terms ''selected sites,'' ''selected subjects,'' and ''selected data'' will be used to describe the sites, subjects, and data fields selected for fabrication. Three additional sites were selected for deletion of adverse event (AE) data.
Fabrication of Data
Seven physicians actively practicing medicine were requested to create fabricated data. All physicians had experience conducting clinical studies (average of 12.8 industry-sponsored pulmonology studies as principal investigator). No physician was employed by a pharmaceutical company. The independent expert clinicians were blinded to the analysis plan. Each physician was provided with an Excel workbook containing data from all ''selected subjects'' plus 2 reference subjects from a selected site with all data intact. Physicians were provided demography, medical history, smoking history, concomitant medications at screening, and clinical laboratory data at screening in addition to the ''selected data'' fields. Physicians were asked to fill the missing ''selected data'' with plausible fabricated data. Approximately half of the AEs were removed from the 3 sites selected for the AE component, leaving only AEs with mild severity at these sites.
Maintaining Plausibility of the Fabricated Data
After the physicians returned the completed Excel workbooks, the fabricated data were corrected by the corresponding author (D.K.), who was not directly involved in the fraud detection method assessment. These corrections included the following:
Pervasive repeated data copying: If numerous values were repeated within a single patient, some values were slightly adjusted. Decimal errors: for example, an FVC value of 38.34 was corrected to 3.834. For technical reasons, each spirometry data time point (FEV1 and FVC) must contain a value that is the duplicate of the highest of the remaining values. If this was not done by the physician, the second-to-lowest value for the time point was replaced with a duplicate of the highest value. Two physicians did not complete the fabricated data for all ''selected subjects.'' Fabricated data from the completed ''selected subjects'' was copied to the blank ''selected subjects'' after adjusting the data for the difference in screening measurements for the ''selected subjects.''
Implanting Fabricated Data
Prior to implantation of the fabricated data into the database, all sites with zero subjects were removed. Actual data for the selected sites and subjects were replaced with fabricated data. The total amount of data did not increase or decrease; if a measurement was missing in the original data set, it remained missing in the final data set.
Creation of Databases for 4 Simulated Studies Differing in Data Volume
The entire data set included 2996 subjects across 178 sites in the US. Screen failure subjects were removed prior to this experiment. To test statistical monitoring in high-and low-data volume conditions, 4 simulated study databases were created by randomly removing sites and subjects from the data set. The simulated studies included all 7 ''selected sites,'' but studies 2A and 1A contained a portion of the ''selected subjects.''
Interpretation Team
The interpretation team included data managers, clinicians, statisticians, and site monitors from TransCelerate member companies as well as members of the independent analysis center (IAC; described below). The physicians who created the fabricated data did not participate in the interpretation team. This team reviewed statistical output, made recommendations for further analyses, and developed a method to flag sites and subjects for potentially fraudulent data.
Independent Analysis Center
The Emmes Corporation (Rockville, MD) participated as the IAC. They were blinded to the methodology for preparing the databases, including the number of sites, number of subjects, and data fields selected for data fabrication. The statistical analysis plan (SAP), blank case report forms, protocol, prepared data sets, and data dictionaries were submitted to the IAC, which provided statistical output and findings to the interpretation team.
Statistical Analysis Plan
A statistical analysis plan (SAP) was developed by statisticians from participating TransCelerate member companies with subsequent input from the interpretation team. The statisticians were told of the study design but were blinded to the specific data fields selected for fabrication. The data panels identified in the SAP included vital signs (SBP, DBP, height, weight, and heart rate), spirometry variables (FEV1 and FVC), AEs, visit dates, and the date of the first dose. The purpose of the methods chosen was to assess how various analyses proposed in the literature were effective in detecting implanted fabricated data as well as data that may signal misconduct. Data anomalies were detected by comparing individual subject or site measurements against aggregated measurements from all subjects or sites. The following data-quality evaluations were specified in the SAP:
Visit date check for holidays and weekends Any visit occurring on a Sunday or US federal holiday.
Visit timing
Distribution of visit lag (distance of actual visit date relative to the target date) on site and subject levels, and enrollment rates by site and month.
Interrelation of the assessments:
Standard deviation (SD): The SD of measures across visits for each subject for vital signs and spirometry measurements. Studywide versus subject-specific confidence intervals (CIs) were compared assuming a ¼ 0.00001 for spirometry analyses and a ¼ 0.001 for vital signs analyses to accommodate multiple testing adjustments balanced against the percentage of sites or subjects ultimately flagged. Also, a repeated-measures model was used for the SD estimates. 11 Correlation: Subject-, site-, and study-level correlations were obtained between SBP, DBP, and pulse and between FEV1, FVC, and their ratios. Comparisons for flagging purposes were made using the CI approach. The ''Proc Freq'' feature in SAS (SAS Institute, Cary, NC) was used for calculation of Pearson correlation and the Wald approach to calculate CIs. Mahalanobis distance (MD) 12 : The MD for each subject as compared to the studywide value was calculated separately for vital signs and spirometry measurements. A large MD for a subject would correspond to an outlier, and a small MD would correspond to an inlier.
Carryover effect/repeated values Carryover, defined as an exact match of a value for a subject from one visit to the next, was calculated. Repeated values, defined as the number of identical values for a subject within a visit (for spirometry) or overall, were calculated.
Digit preference and rounding
For each subject, last digit frequency distribution was compared to other subjects at that site and across the study using either a w 2 or Fisher exact test, as appropriate, and by comparing the mean and SD of last digit value within a subject to studywide distributions using the CI approach.
Missing data
The rate of missing data was calculated by dividing the number of missed measures by the number of times it was expected.
AE reporting frequency
The AE rate per person-week of time on study was calculated. Subjects with no AEs but who were in the top 10% of prestudy comorbidity prevalence and sites where 80% of all AEs were of a single severity level were flagged.
Additional analyses were performed to examine potential data inconsistencies, including subject-level values by site showing the average study value across time, within site average values over time, and 95% CIs, and individual subject-level values across time. All analyses were conducted in R 13 (The R Project for Statistical Computing; https://www.r-project.org/) and SAS 9.3 and 9.4. 14
Results

An Algorithm for Detecting Fabricated Data
The interpretation team reviewed graphical data summaries. For example, Figure 1 depicts the distribution of the FEV1/ FVC ratio for a site with suspected data fabrication (''odd site'') and a ''reference site'' not suspected of having fabricated data in studies 2A and 1.
This graphical summary quickly identified a site with an unusual data pattern without any statistical testing even with only 2 subjects randomized at the ''odd site'' in study 2A. However, most sites were not so graphically apparent, and statistical testing was required to detect statistical significance. Given the number of sites and subjects, a more structured and automated approach was explored.
The interpretation team created a study-specific algorithm to flag subjects and sites with potentially fabricated data as well as other types of noncompliance. The interpretation team reviewed output from the 4 studies from smallest to largest, starting with study 2A. A spreadsheet was created that summarized statistically significant results in any of the examined domains at both site and subject levels. Sites and subjects were classified as low-, moderate-, or high-suspicion. Through iterative rounds of data review and discussion, a team consensus developed regarding the utility of various statistical methods and outputs. Discussions focused on the likelihood that certain findings could be due to chance or would be clinically highly unlikely. For example, in the spirometry domain, the interpretation team put heavier weight on statistically significant deviations from the expected correlation between FEV1 and FVC and repeated values, given that a device was used for measurement and each included 4 digits (X.XXX format). More variability and repetition of values were expected in vital signs measurements; thus, higher thresholds for flagging a site or subject were used for vital signs. After the discussion of study 2A, the team was unblinded to the variables fabricated, allowing independent focus on fabrication versus other data anomalies suggestive of noncompliance (eg, visit date and missing data that were not involved in fabrication). But the interpretation team remained blinded to ''selected sites'' and ''selected subjects.'' The team reviewed parallel coordinate plots 15 of SDs, carryover/repeated values, correlations, scatter plots of correlations and SDs, and last-digit histograms and distributions. The key statistical methods for identifying potentially fabricated data were repeated values and the CI approach for correlations, SDs, and last-digit preferences for both spirometry and vital signs variables. An algorithm that scored each subject's result in each of these areas with a 0, 1, or 2 was developed; this algorithm applied heavier weights to spirometry anomalies (2) than to vital anomalies (1). A subject score was calculated by summing the scores across domains within subject. A subject was flagged if the subject's score in either domain (spirometry or vitals) exceeded a threshold value selected by the team. A site was flagged if it had at least 4 subjects, and 25% or more of the subject scores exceeded a site-level threshold value selected by the team or if an individual site had a least one flagged subject, regardless of the number of subjects at the site. This approach allowed small sites (fewer than 4 subjects) to be flagged.
The algorithm was applied to studies 2, 1A, and 1, after which the team was unblinded to the actual sites and subjects with fabricated data. The algorithm diagnostics of sensitivity and specificity at the site and subject level were calculated using this unblinded information. Because the technique for fabrication differed between spirometry and vital data compared to AE data, separate analyses were performed to detect fabricated data corresponding to AEs. In addition, signals of protocol noncompliance and other data anomalies not associated with the fabricated data were identified.
Site-Level Outcomes
The prevalence of ''selected sites'' ranged from 11% of sites to 4% ( Table 1 ). The algorithm was applied without adjustment for the size of the study. Results from the algorithm identified 11 sites (19%), 19 sites (31%), 28 sites (16%), and 45 sites (25%) as having potentially fabricated data for studies 2A, 2, 1A, and 1, respectively. The proportion of ''selected sites'' detected by the algorithm increased with study size from 3/7 (43%) in study 2A to 6/7 (86%) in study 1. Except for study 2A, the algorithm had good sensitivity and specificity (>70%) for identifying sites with fabricated data. The negative predictive value, or the proportion of sites not flagged that did not have fraudulent data, exceeded 90% for all studies.
Other individual statistical approaches executed as part of the analysis plan did not demonstrate improved performance in terms of sensitivity or specificity. When last-digit preference across all variables (spirometry and vital signs data combined) was tested, we found high false-positive rates. The MD of spirometry data identified at most 3 of the ''selected'' sites. The mixed-model approach to estimating SDs did not improve identification of ''selected'' sites. Carryover proved less useful than exact repeated values, with only one of the ''selected'' sites having a very high rate of carryover. Selecting a specific preference for BP data ending in 0 or 5 also did not yield additional value. In study 2A, although 4 ''selected'' sites were flagged by this criterion, only 3 subjects at those sites were ''selected.''
Subject-Level Outcomes
Subject scores from the algorithm resulted in approximately one-third of subjects being identified as potentially having fabricated data across all 4 studies with sensitivity near 80% and specificity just over 70% ( Table 2 ). Negative predictive value was 97% across all studies.
An evaluation of the components of the algorithm showed that correlation and repeated values should have a higher weight in the spirometry domain compared with vital signs. Figure 2 shows a scatter plot of individual subject-level Without vital signs in the algorithm, approximately 40% of subjects in each study would be flagged, sensitivity would increase to 80%, but specificity would drop to about 60%. Within the statistical methods chosen for vital signs score (SD, correlation, digit preference, and repeat values), the SD had the best performance in terms of sensitivity, specificity, and positive and negative predictive values. Site-level sensitivity using this measure alone ranged from 41% to 53%, and specificity was about 90%. Only 9% to 14% of ''selected'' subjects would be flagged (data not shown).
Adverse Event Anomaly Detection
Three approaches to AE detection were taken, and the approach that flagged sites based on a greater than 80% severity type prevalence successfully identified all ''selected'' sites within each study. Flagging based on lower-than-expected event rates identified a number of sites of concern although it was not successful for the fabrication approach selected for this experiment.
Other Analyses
Evaluation of visit lag distributions, holiday and Sunday visits, and missed visits identified several sites with unusual visit timing or missed visits; however, none of the identified data had been fabricated.
Discussion
Errors can have many etiologies. Data errors from causes such as equipment miscalibration produce clear shifts in the mean and are easy to detect. Other easily detectable patterns include protocol misinterpretation by whole sites or countries because these errors produce mean shifts in a whole group of data compared to the aggregate. Conversely, intentional patientlevel data fabrication can be much more difficult to detect because investigators use medical and scientific knowledge to construct clinically plausible data. This experiment focused on detecting fabricated data intentionally created by knowledgeable clinicians specifically asked to act in a manner likely to evade detection.
O'Kelly 8 tested various statistical methods in subjective data (Montgomery-Å sberg Depression Rating Scale [MADRS] scores) and noted challenges with performing evaluations of means and correlations. Subjective measures may not be good candidates for statistical monitoring. Pogue et al 9 and Wu and Carlsson 10 handpicked sites from a large study so that each site had approximately 20 subjects, a condition not likely to exist during study conduct. Kirkwood et al 6 intentionally planted ''easy to detect'' fabricated data and found that some statistical assessments were not applicable for sites with fewer than 10 subjects. In the present experiment, a COPD study was chosen because of the objectivity of measurements (actual spirometry data were instrument generated and vital signs data were collected by various methods).
This project tested statistical monitoring methods on a queried and cleaned pharmaceutical industry-sponsored clinical study database with implanted fabricated data in high-and low-data volume conditions mimicking conditions found during study conduct. The project evaluated a battery of statistical methods, report types, and graphical displays to identify strategies most useful to flag sites and subjects as anomalous. A SAP included site-level exploration of reported data with respect to visit lag, Sunday or holiday visits, enrollment patterns, digit preference, repeat data values, carryover of values, and exploration of data distributions, variance, and correlations of key variables over time by subject compared to site-level and study-level distributions. A data-science model with an interdisciplinary interpretation team was used to evaluate statistical results. Review of the output for the smallest study by the interpretation team resulted in an algorithm applied to the 3 progressively larger studies. No single statistical approach was adequate, and the algorithm using a combination of statistical approaches provided better performance than any individual statistical test. The exact formula for this algorithm is not provided because it is the process we describe that we suggest could be replicated by others-regardless of disease or location of study sites-rather than the unique formula developed for this study. Identification of data issues should occur early during study conduct to allow for corrective action. Our results suggest utility of centrally reviewing queried and cleaned data even during the early phase of a study. Distributions (Figure 1 ), even early in study conduct, could show issues that can be corrected before more subjects are enrolled. Review of outliers in values, SDs, or correlations may identify queries or range checks that need to be systematically implemented.
A variety of methods have been proposed to explore accumulating data in clinical studies, with general agreement regarding the potential benefit of SD analyses, MD measures to detect inliers and outliers, carryover or repeated measures, and correlations. 3, 5 Inliers may be more indicative of fraud, whereas outliers may indicate sloppiness in data collection.
The current experiment evaluated each of these approaches and found that a multidisciplinary interpretation team reviewing and discussing the relevance of the statistical findings to the clinical condition and the data collection methods was critical to the formulation of the algorithm. The interpretation team chose to assign more weight to statistically significant subject deviations in the most objective data (spirometry data) than in vital signs data, which had more variability in collection techniques. The final result had acceptable sensitivity and false-negative rates in all studies except for the smallest study (2A). There was one ''selected site'' that the algorithm failed to find in any of the study conditions. For this site, the implanted data was only partially fabricated by the physician collaborator, who did not complete the selected cases; consequently, the corresponding author (D.K.) fabricated data for the remaining selected subjects. It is possible that the author's intimate knowledge of the SAP may have influenced the data fabrication; however, this does not fully explain the failure to detect this site. The effectiveness of statistical monitoring has been questioned under low-data volume conditions. 4, 6 Small sample sizes within sites can limit the likelihood of statistical methods to flag a site and may hamper parametric statistical testing. The final algorithm used for this experiment scored each subject against studywide values and subsequently scored the site based on the subject scores. This approach may provide protection from missing a single subject at a small site; however, flagging a small site because of a single subject may increase false-positive rates. An adaptive algorithm that uses different cut-offs for subject and site flagging depending on the stage and size of the study may be prudent.
In cases where the site personnel performing a procedure (examiner) is identified in a database, cross-examiner data comparisons could be performed to look for patterns. If only subjects examined by one individual are flagged, then further investigation is warranted. Although fabricated data at large sites is likely to have a more significant impact on study result reliability, we recommend all sites be reviewed. For very large studies, a staged approach that begins with automated screening to flag sites based on statistical testing followed by more detailed investigation of flagged sites may be more practical then initial review of output from all sites.
The experimental design did not truly replicate real-world conditions, so generalizability is limited, and the diminishing prevalence of ''selected subjects'' across the 4 study conditions makes comparisons of the positive and negative predictive values across studies problematic. Although this data set had been cleaned and locked, it is possible that some of the sites listed as false-positives are in fact true-positives due to calibration issues in spirometers, training, or other factors. Some of the outliers found by MD analysis could have been readily discovered via routine data range checks. Three of our 7 independent expert clinicians made errors in the fabricated data that were obvious from a cursory review, and 2 failed to complete all subjects and left many fields blank. The choice of weights as part of a flagging algorithm, adjustments for multiple comparisons, and the use of cut points (eg, percentage of repeat values) should be driven by clinical relevance, thus subjective and variable from study to study and across interpretation teams. In our algorithm, we chose multiple comparison alpha adjustments and thresholds so that approximately 25% of sites would be flagged. Whether other approaches to algorithm creation implemented in other studies would have the same properties is unknown. An algorithm derived by an actual study team that includes clinicians and statisticians working together over an extended time frame with intensive knowledge of the protocol and lessons learned from predecessor studies would be expected to have better performance. For example, the actual study team found that the dose-response curve formed by the FEV1 and FVC was the best approach to assess the biological plausibility of spirometry data. The IAC and interpretation team did not have enough information to apply this approach. Also, the interpretation team only had 2 weeks working together to interpret and refine the statistical approach, did not receive the protocol prior to review of the statistical output, and had not previously worked with each other. Finally, although our experiment included a ''small study,'' it can be argued that the ''small study'' did not adequately test statistical methods in truly small studies (eg, 30 sites and 3 subjects per site).
Conclusions and Recommendations
We recommend that statistical monitoring within a datascience approach be considered to augment other study quality management activities, including on-site monitoring and review of risk indicators. 16 Consistent with previous authors, 4, 5 we caution using unqueried data for statistical assessment. To Statistical monitoring should be performed iteratively throughout a study starting as soon as there is adequate data volume and at a frequency determined by the pace of data collection or aligned with cohort cleaning or DSMB submission schedules. Small, rapidly enrolling studies may receive limited benefit from many statistical methods during study conduct except when extreme outliers are present; however, some graphical techniques may be useful when low-data volume conditions exist, including early during study conduct. The utility of graphical techniques may be highest early in a study, or within a small study, while algorithm application may be more useful later in a study with a large number of sites (eg, >100 sites) and subjects (eg, >6 subjects/site).
Using a study-specific algorithm, large amounts of data can be reviewed at multiple stages during the study with minimal time expenditure. Discussions of statistical monitoring algorithms should be initiated during study planning and refined throughout the study. Algorithms should never be known to the site investigators.
We suggest a process that includes 1. creation of a statistical monitoring SAP, 2. creation of a cross-functional interpretation team, 3. review of statistical results by the interpretation team, 4. development of a scoring algorithm for consistency and efficiency, and 5. application of the algorithm with interpretation team review and adjustment throughout the study.
The statistical monitoring field is in development, and we encourage further investigation of best practices and reporting on methods found to be successful in improving data quality and integrity. Further work is particularly needed regarding the application of statistical monitoring in low-data volume conditions, including few subjects per site and few study visits per subject, as is characteristic early during study conduct. This study recommends the utility of a cross-functional, collaborative approach to statistical monitoring rather than a fully automated approach. The approach should be adapted to study design and data source and should use a combination of statistical screening techniques and confirmatory graphics reviewed by a multidisciplinary interpretation team.
